(Q38006431)

26 August 2017

title

Molecular therapies for tuberous sclerosis and neurofibromatosis (English)

1 reference

26 August 2017

1 reference

David Neal Franz

1

1 reference

26 August 2017

Brian D Weiss

series ordinal

2

1 reference

26 August 2017

publication date

1 June 2012

1 reference

Current Neurology and Neuroscience Reports

26 August 2017

published in

1 reference

26 August 2017

volume

12

1 reference

26 August 2017

issue

3

1 reference

26 August 2017

page(s)

294-301

1 reference

Treatment of acute lymphoblastic leukemia

26 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Children's Cancer Group trials in childhood acute lymphoblastic leukemia: 1983-1995.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The NF1 tumor suppressor critically regulates TSC2 and mTOR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Proteomic analysis reveals hyperactivation of the mammalian target of rapamycin pathway in neurofibromatosis 1-associated human and mouse brain tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

21 January 2018

The two TORCs and Akt.

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Malignancy in neurofibromatosis type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

21 January 2018

Plexiform neurofibromas

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Prognostic signs in the surgical management of plexiform neurofibroma: the Children's Hospital of Philadelphia experience, 1974-1994.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Von Recklinghausen neurofibromatosis. A clinical and population study in south-east Wales.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Mortality in neurofibromatosis 1: an analysis using U.S. death certificates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis complex: neurological, renal and pulmonary manifestations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The pathogenesis and imaging of the tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Hereditary neuroendocrine tumors of the gastroenteropancreatic system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis complex and epilepsy: recent developments and future challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

PEComas: the past, the present and the future

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Mechanisms of epileptogenesis in tuberous sclerosis complex and related malformations of cortical development with abnormal glioneuronal proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Behavior problems in children with tuberous sclerosis complex and parental stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Subependymal giant cell tumors in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Prevalence of subependymal giant cell tumors in patients with tuberous sclerosis and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Current trends in the treatment of infantile spasms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

From mTOR to cognition: molecular and cellular mechanisms of cognitive impairments in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Attention-deficit hyperactivity disorder (ADHD) and tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Cognitive prognosis of patients with tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Angiomyolipomata: challenges, solutions, and future prospects based on over 100 cases treated

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Lymphangioleiomyomatosis: a clinical update.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Molecular activity of sirolimus and its possible application in tuberous sclerosis treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Perinatal (fetal and neonatal) tuberous sclerosis: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

TORC1 is essential for NF1-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Genetics and molecular biology of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Dissecting the role of mTOR: lessons from mTOR inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis complex proteins control axon formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The tuberous sclerosis complex proteins--a GRIPP on cognition and neurodevelopment

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Diffusion features of white matter in tuberous sclerosis with tractography

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Recent advances in neurobiology of Tuberous Sclerosis Complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Role of mTOR in physiology and pathology of the nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Regulation of neuronal morphology and function by the tumor suppressors Tsc1 and Tsc2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Epilepsy secondary to tuberous sclerosis: lessons learned and current challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Reversal of learning deficits in a Tsc2+/- mouse model of tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Therapeutic targeting of mTOR in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Mammalian target of rapamycin (mTOR) inhibition as a potential antiepileptogenic therapy: From tuberous sclerosis to common acquired epilepsies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Rapamycin prevents epilepsy in a mouse model of tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Novel molecular and cellular therapeutic targets in acute lymphoblastic leukemia and lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Rapamycin regulates the phosphorylation of rictor

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Rapamycin derivatives reduce mTORC2 signaling and inhibit AKT activation in AML.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Rapamycin in transplantation: a review of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Rapamycin causes regression of astrocytomas in tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Sirolimus for angiomyolipoma in tuberous sclerosis complex or lymphangioleiomyomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Management of epilepsy in tuberous sclerosis complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Current management of tuberous sclerosis complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Tuberous sclerosis complex: a brave new world?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Cardiac rhabdomyoma in tuberous sclerosis: hyperactive Erk signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

Cardiac rhabdomyomas in tuberous sclerosis complex show apoptosis regulation and mTOR pathway abnormalities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11910-012-0269-4

21 January 2018

1 reference

12 December 2020

Phase I trial of pirfenidone in children with neurofibromatosis 1 and plexiform neurofibromas

1 reference

12 December 2020

Malignant peripheral nerve sheath tumours in neurofibromatosis 1

1 reference

12 December 2020

The role of the preBCR, the interleukin-7 receptor, and homotypic interactions during B-cell development

1 reference

12 December 2020

Increased survival of children with solid tumours: how did we get there and how to keep the success going?

1 reference

12 December 2020

Behavioral and cognitive aspects of tuberous sclerosis complex

1 reference

12 December 2020

Epilepsy surgery for children with tuberous sclerosis complex

1 reference

12 December 2020

Non-neurologic manifestations of tuberous sclerosis complex

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization

1 reference

12 December 2020

Epithelioid angiomyolipoma: a morphologically distinct variant that mimics a variety of intra-abdominal neoplasms

1 reference

12 December 2020

mTOR as a target for cancer therapy.

1 reference

12 December 2020

Lymphangioleiomyomatosis

1 reference

12 December 2020

1 reference

12 December 2020

Managing epilepsy in tuberous sclerosis complex

1 reference

12 December 2020

Pediatric Malignant Peripheral Nerve Sheath Tumor: The Italian and German Soft Tissue Sarcoma Cooperative Group

1 reference

12 December 2020

Mutational analysis of the TSC1 and TSC2 genes in a diagnostic setting: genotype--phenotype correlations and comparison of diagnostic DNA techniques in Tuberous Sclerosis Complex

1 reference

12 December 2020

Are cortical tubers epileptogenic? Evidence from electrocorticography

1 reference

12 December 2020

Molecular pathogenesis of tuber formation in tuberous sclerosis complex

1 reference

12 December 2020

Rapamycin (AY-22,989), a new antifungal antibiotic. II. Fermentation, isolation and characterization.

1 reference

12 April 2024

https://opencitations.net/index/api/v1/citations/10.7164/ANTIBIOTICS.28.727

Identifiers

DOI

10.1007/S11910-012-0269-4

1 reference

Dimensions Publication ID

26 August 2017

1031552533

0 references

1 reference